» Articles » PMID: 29142479

Medication Beliefs Predict Medication Adherence in Ambulatory Patients with Decompensated Cirrhosis

Abstract

Aim: To investigate the impact of medication beliefs, illness perceptions and quality of life on medication adherence in people with decompensated cirrhosis.

Methods: One hundred adults with decompensated cirrhosis completed a structured questionnaire when they attended for routine outpatient hepatology review. Measures of self-reported medication adherence (Morisky Medication Adherence Scale), beliefs surrounding medications (Beliefs about Medicines Questionnaire), perceptions of illness and medicines (Brief Illness Perception Questionnaire), and quality of life (Chronic Liver Disease Questionnaire) were examined. Clinical data were obtained patient history and review of medical records. Least absolute shrinkage and selection operator and stepwise backwards regression techniques were used to construct the multivariable logistic regression model. Statistical significance was set at alpha = 0.05.

Results: Medication adherence was "High" in 42% of participants, "Medium" in 37%, and "Low" in 21%. Compared to patients with "High" adherence, those with "Medium" or "Low" adherence were more likely to report difficulty affording their medications ( < 0.001), lower perception of treatment helpfulness ( = 0.003) and stronger medication concerns relative to medication necessity beliefs ( = 0.003). People with "Low" adherence also experienced greater symptom burden and poorer quality of life, including more frequent abdominal pain ( = 0.023), shortness of breath ( = 0.030), and emotional disturbances ( = 0.050). Multivariable analysis identified having stronger medication concerns relative to necessity beliefs (Necessity-Concerns Differential ≤ 5, OR = 3.66, 95%CI: 1.18-11.40) and more frequent shortness of breath (shortness of breath score ≤ 3, OR = 3.87, 95%CI: 1.22-12.25) as independent predictors of "Low"adherence.

Conclusion: The association between "Low" adherence and patients having strong concerns or doubting the necessity or helpfulness of their medications should be explored further given the clinical relevance.

Citing Articles

Key Factors of Adherence in Cardiological Follow-Up of Adults with Congenital Heart Disease.

Ehmann A, Schutte E, Semmler J, Berger F, Bauer U, Schmitt K J Cardiovasc Dev Dis. 2025; 12(2).

PMID: 39997473 PMC: 11856703. DOI: 10.3390/jcdd12020039.


The Evolution in Non-Alcoholic Fatty Liver Disease Patients' Profile and the Associated Sustainable Challenges: A Multidisciplinary Perspective.

Aerts M, Rosseel Z, De Waele E Nutrients. 2024; 16(11).

PMID: 38892517 PMC: 11174485. DOI: 10.3390/nu16111584.


Medication Beliefs, Cognitive Defusion, and Valued Living in Hypertensive Patients with Varying Medication Adherence.

Zargar F, Monzavi P, Tarrahi M, Salehi S ARYA Atheroscler. 2024; 19(1):17-24.

PMID: 38883155 PMC: 11079295. DOI: 10.48305/arya.2022.11811.2471.


A Predictive Model for Identifying Low Medication Adherence Among Patients with Cirrhosis.

Wang N, Li P, Suo D, Wei H, Wei H, Guo R Patient Prefer Adherence. 2023; 17:2749-2760.

PMID: 37933304 PMC: 10625737. DOI: 10.2147/PPA.S426844.


Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life.

Farooq J, Sana M, Chetana P, Almuqbil M, Prabhakar Bhat N, Sultana R Saudi Pharm J. 2023; 31(8):101668.

PMID: 37576859 PMC: 10415215. DOI: 10.1016/j.jsps.2023.06.001.


References
1.
Arvaniti V, DAmico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M . Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010; 139(4):1246-56, 1256.e1-5. DOI: 10.1053/j.gastro.2010.06.019. View

2.
Simpson S, Eurich D, Majumdar S, Padwal R, Tsuyuki R, Varney J . A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333(7557):15. PMC: 1488752. DOI: 10.1136/bmj.38875.675486.55. View

3.
Krousel-Wood M, Islam T, Webber L, Re R, Morisky D, Muntner P . New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009; 15(1):59-66. PMC: 2728593. View

4.
Bajaj J, Sanyal A, Bell D, Gilles H, Heuman D . Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther. 2010; 31(9):1012-7. DOI: 10.1111/j.1365-2036.2010.04257.x. View

5.
Leevy C, Phillips J . Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007; 52(3):737-41. DOI: 10.1007/s10620-006-9442-4. View